A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Sponsor study identifier
observational
16
1 country
11
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2010
Actual (reported)Study Completion
February 2010
Actual (reported)This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)September 16, 2005
Actual (reported)February 2010
Actual (reported)February 2010
Actual (reported)Incidence of grade 3 or 4 allergic reactions
Within 30 days of last treatment administration
Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients at high risk of tumor lysis syndrome who have a history of asthma, eczema, or significant allergies (to substances other than rasburicase).
Stanford University
Palo Alto, California, 94304, United States
Rady Children's Hospital
San Diego, California, 92123, United States
Peyton Manning Children's Hospital at St. Vincent
Indianapolis, Indiana, 46260, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115-6084, United States
Children's Hospital Michigan
Detroit, Michigan, 48201, United States
Columbia University Medical Center
New York, New York, 10032, United States
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Raul C. Ribeiro, MD
St. Jude Children's Research Hospital
16 participants (actual enrollment reported by the registry).
First Submitted
September 12, 2005
First Posted
September 16, 2005
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
St.Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Mid-West Children's Cancer Center
Milwaukee, Wisconsin, 53226-4801, United States
Primary Completion
February 2010
Actual (reported)Study Completion
February 2010
Actual (reported)Last Updated
April 25, 2017
Record last verified: 2011-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: